BLOG
Accelerating the implementation of medical application scenarios
Apr 15,2025
In the third week of February 2025, the pharmaceutical and biological sector will continue its structural differentiation trend. The pharmaceutical and biological index rose 1.88% for the whole week, outperforming the Shanghai and Shenzhen 300 and Shanghai Composite Index, ranking 9th in terms of industry gains and losses. In the segmented field, medical R&D outsourcing led the way with an increase of 11.3%, while offline pharmacies fell by 3.06%, becoming the weakest performing sub industry. In terms of sector valuation, the current PE (TTM) is 26 times, still in the low range of nearly a decade. Market funds continue to gather towards hard technologies such as innovative drugs and AI healthcare, and the positive signals released by policies further strengthen the expectation of a bottoming out in the industry. Despite the broad prospects of AI healthcare, its development still faces challenges such as data compliance and long clinical validation cycles. The current market tends to focus on midstream platform companies that integrate algorithms, data, and clinical resources for "AI+healthcare", which can quickly achieve technology migration. At the same time, the synergistic effect between emerging technologies such as stem cell therapy and gene editing and AI is gradually emerging, which may become an important track for industrial competition in the next stage. It is worth noting that the balance between technological iteration speed and regulatory adaptability will become a key variable determining the pace of industry growth.
In the third week of February 2025, the pharmaceutical and biological sector will continue its structural differentiation trend. The pharmaceutical and biological index rose 1.88% for the whole week, outperforming the Shanghai and Shenzhen 300 and Shanghai Composite Index, ranking 9th in terms of industry gains and losses. In the segmented field, medical R&D outsourcing led the way with an increase of 11.3%, while offline pharmacies fell by 3.06%, becoming the weakest performing sub industry. In terms of sector valuation, the current PE (TTM) is 26 times, still in the low range of nearly a decade. Market funds continue to gather towards hard technologies such as innovative drugs and AI healthcare, and the positive signals released by policies further strengthen the expectation of a bottoming out in the industry.
Despite the broad prospects of AI healthcare, its development still faces challenges such as data compliance and long clinical validation cycles. The current market tends to focus on midstream platform companies that integrate algorithms, data, and clinical resources for "AI+healthcare", which can quickly achieve technology migration. At the same time, the synergistic effect between emerging technologies such as stem cell therapy and gene editing and AI is gradually emerging, which may become an important track for industrial competition in the next stage. It is worth noting that the balance between technological iteration speed and regulatory adaptability will become a key variable determining the pace of industry growth.
Recommended News
Share
Contact Us
Tel/WhatsApp:
E-mail:
Add:
Room 801, building 3,| No.518 Xinzhuan Road | Songjiang | Shanghai | 201612.China
Message
JINGJIN GROUP
Online Consultation